Jefferies starts Judges Scientific at ‘buy’ after share price correction.


Jefferies initiated coverage on Judges Scientific on Tuesday with a ‘buy’ rating and 12,230p price target, as it said the valuation is more attractive following the recent share price correction, particularly if potential M&A upside is considered.

  • Judges Scientific
  • 03 September 2024 11:01:51
Judges Scientific

Source: Sharecast

"We see Judges as one of the highest-quality names in the sector, due to its impressive track record of value creation, margin expansion and growth, and we believe the recent share price correction has created an attractive entry point, with the stock now trading at discounts to five-year average multiples," it said.

Jefferies pointed out that Judges is focused on buying scientific instrumentation companies with strictly defined characteristics and performance criteria, which has resulted in a 21% revenue compound annual growth rate and 28% EBITA CAGR from FY06 - FY23, with margins growing 1,190 basis points.

"The company's balance sheet offers ample headroom, and our M&A scenario analysis shows potential for 4-17% earnings per share accretion in FY25F at a leverage range of only 1.0x-1.7x," it said.

At 1015 BST, the shares were up 1.4% at 10,390p.


N/A

ISIN: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.